A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Actuate Therapeutics Inc.
Bristol-Myers Squibb
AstraZeneca
Eli Lilly and Company
OHSU Knight Cancer Institute
Maastricht University Medical Center
Eli Lilly and Company
DEKA Biosciences
Eli Lilly and Company
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Emory University
Gilead Sciences
National Cancer Institute (NCI)
Celgene
National Cancer Institute (NCI)
City of Hope Medical Center